Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts

Irina V. Balyasnikova, Sherise D. Ferguson, Yu Han, Feifei Liu, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Treatment of glioblastoma remains a challenge in neuro-oncology. We investigated if treatment with neural stem cells engineered to express membrane-bound TRAIL (NSCs-mTRAIL) alone or in combination with proteasome inhibitors is a feasible therapeutic approach for experimental glioma. Glioma cells showed resistance to soluble TRAIL and proteasome inhibitors alone, but responded well to their combined treatment. In co-culture with NSCs-mTRAIL, glioma cells appeared to be more prone to apoptosis than to treatment with soluble TRAIL, which was enhanced by proteasome inhibitor bortezomib. In vivo, the survival of animals bearing intracranial glial xenografts was significantly improved by NSCs-mTRAIL. The addition of bortezomib further enhanced the efficacy of NSCs-TRAIL treated group in one of examined tumor models. These data demonstrate that therapy with NSCs-mTRAIL is a potent cell based approach for treatment of glioma. Such an approach warrants further search for therapeutics capable of increasing sensitivity of glioma cells to mTRAIL in vivo.

Original languageEnglish (US)
Pages (from-to)148-159
Number of pages12
JournalCancer Letters
Volume310
Issue number2
DOIs
StatePublished - Nov 28 2011

Fingerprint

Neural Stem Cells
Therapeutic Uses
Heterografts
Glioma
Proteasome Inhibitors
Membranes
Glioblastoma
Coculture Techniques
Neuroglia
Therapeutics
Bortezomib
Apoptosis
Neoplasms

Keywords

  • Bortezomib
  • Brain cancer
  • Glioma
  • Neural stem cells
  • TRAIL

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{bd7f7b707bac4aa6b8f0791f425b27e9,
title = "Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts",
abstract = "Treatment of glioblastoma remains a challenge in neuro-oncology. We investigated if treatment with neural stem cells engineered to express membrane-bound TRAIL (NSCs-mTRAIL) alone or in combination with proteasome inhibitors is a feasible therapeutic approach for experimental glioma. Glioma cells showed resistance to soluble TRAIL and proteasome inhibitors alone, but responded well to their combined treatment. In co-culture with NSCs-mTRAIL, glioma cells appeared to be more prone to apoptosis than to treatment with soluble TRAIL, which was enhanced by proteasome inhibitor bortezomib. In vivo, the survival of animals bearing intracranial glial xenografts was significantly improved by NSCs-mTRAIL. The addition of bortezomib further enhanced the efficacy of NSCs-TRAIL treated group in one of examined tumor models. These data demonstrate that therapy with NSCs-mTRAIL is a potent cell based approach for treatment of glioma. Such an approach warrants further search for therapeutics capable of increasing sensitivity of glioma cells to mTRAIL in vivo.",
keywords = "Bortezomib, Brain cancer, Glioma, Neural stem cells, TRAIL",
author = "Balyasnikova, {Irina V.} and Ferguson, {Sherise D.} and Yu Han and Feifei Liu and Lesniak, {Maciej S.}",
year = "2011",
month = "11",
day = "28",
doi = "10.1016/j.canlet.2011.06.029",
language = "English (US)",
volume = "310",
pages = "148--159",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts. / Balyasnikova, Irina V.; Ferguson, Sherise D.; Han, Yu; Liu, Feifei; Lesniak, Maciej S.

In: Cancer Letters, Vol. 310, No. 2, 28.11.2011, p. 148-159.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in mice with glioma xenografts

AU - Balyasnikova, Irina V.

AU - Ferguson, Sherise D.

AU - Han, Yu

AU - Liu, Feifei

AU - Lesniak, Maciej S.

PY - 2011/11/28

Y1 - 2011/11/28

N2 - Treatment of glioblastoma remains a challenge in neuro-oncology. We investigated if treatment with neural stem cells engineered to express membrane-bound TRAIL (NSCs-mTRAIL) alone or in combination with proteasome inhibitors is a feasible therapeutic approach for experimental glioma. Glioma cells showed resistance to soluble TRAIL and proteasome inhibitors alone, but responded well to their combined treatment. In co-culture with NSCs-mTRAIL, glioma cells appeared to be more prone to apoptosis than to treatment with soluble TRAIL, which was enhanced by proteasome inhibitor bortezomib. In vivo, the survival of animals bearing intracranial glial xenografts was significantly improved by NSCs-mTRAIL. The addition of bortezomib further enhanced the efficacy of NSCs-TRAIL treated group in one of examined tumor models. These data demonstrate that therapy with NSCs-mTRAIL is a potent cell based approach for treatment of glioma. Such an approach warrants further search for therapeutics capable of increasing sensitivity of glioma cells to mTRAIL in vivo.

AB - Treatment of glioblastoma remains a challenge in neuro-oncology. We investigated if treatment with neural stem cells engineered to express membrane-bound TRAIL (NSCs-mTRAIL) alone or in combination with proteasome inhibitors is a feasible therapeutic approach for experimental glioma. Glioma cells showed resistance to soluble TRAIL and proteasome inhibitors alone, but responded well to their combined treatment. In co-culture with NSCs-mTRAIL, glioma cells appeared to be more prone to apoptosis than to treatment with soluble TRAIL, which was enhanced by proteasome inhibitor bortezomib. In vivo, the survival of animals bearing intracranial glial xenografts was significantly improved by NSCs-mTRAIL. The addition of bortezomib further enhanced the efficacy of NSCs-TRAIL treated group in one of examined tumor models. These data demonstrate that therapy with NSCs-mTRAIL is a potent cell based approach for treatment of glioma. Such an approach warrants further search for therapeutics capable of increasing sensitivity of glioma cells to mTRAIL in vivo.

KW - Bortezomib

KW - Brain cancer

KW - Glioma

KW - Neural stem cells

KW - TRAIL

UR - http://www.scopus.com/inward/record.url?scp=80051678161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051678161&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2011.06.029

DO - 10.1016/j.canlet.2011.06.029

M3 - Article

VL - 310

SP - 148

EP - 159

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -